Details

New Drug Development for Known and Emerging Viruses

Methods & Principles in Medicinal Chemistry 1. Aufl.

von: Helga Rübsamen-Schaeff, Helmut Buschmann, Raimund Mannhold, Jörg Holenz
CHF 386.00
Verlag:	Wiley-VCH
Format:	PDF
Veröffentl.:	30.11.2021
ISBN/EAN:	9783527810710
Sprache:	englisch
Anzahl Seiten:	528

In den Warenkorb

Als Gutschein

DRM-geschütztes eBook, Sie benötigen z.B. Adobe Digital Editions und eine Adobe ID zum Lesen.

Beschreibungen

Titelbeschreibung

Discusses how to fight Ebola, SARS Corona, and other known or emerging human viruses by building on the successes in antiviral therapy of the past decades Written by leading medicinal chemists from academia and industry, this book discusses the entire field of antiviral drug discovery and development from a medicinal chemistry perspective, focusing on antiviral drugs, targets, and viral disease mechanisms. It provides an outlook on emerging pathogens such as Ebola, Zika, West Nile, Lassa, and includes a chapter on SARS Coronoavirus-2 causing the present pandemic. New Drug Development for Known and Emerging Viruses describes the discovery and development process for antiviral agents for different classes of viruses and targets based on the experiences from the nine human viruses for which approved drugs are on the market (HIV, HCV, Influenza, RSV, HBV, HPV, HCMV, HSV, and VZV). It covers the properties and potential of 20 classes of currently approved antivirals, including combination drugs, and looks at novel antiviral strategies against emerging viruses. <ul> <li>Covers the entire field of antiviral drug discovery and development</li> <li>Addresses the need for antiviral drugs to combat major health threats such as Ebola, Zika, West Nile, and SARS Coronavirus-2</li> <li>Summarizes the successes of the past 15 years in developing ground-breaking medicines against 9 major human viruses, both from the medicinal chemistry and the pharmacological angle</li> <li>Discusses practical and strategic challenges in the drug discovery and development process, including screening technologies, latency, and toxicity issues</li> </ul> New Developments in Antiviral Drugs is an important book for medicinal chemists, pharmaceutical chemists, virologists, and epidemiologists, and will be of great interest to those in the ;pharmaceutical industry and public health agencies.

Inhaltsverzeichnis

Human Immunodeficiency Virus (HIV): Targets for therapy and open issues Human Immunodeficiency Virus (HIV): Anti-HIV drug discovery and development Hepatitis C Virus (HCV): Curing chronic HCV infections Influenza Virus: Targets and drugs Respiratory Syncytial Virus (RSV): Enzymology, antiviral targets, and drugs in development Hepatitis B Virus (HBV): Development of therapeutic vaccines Hepatitis B Virus (HBV): Drug targets Hepatitis B Virus (HBV): Medicinal chemistry of capsid inhibitors Hepatitis B Virus (HBV): Immunomodulators (Replicor and AIC 649) Human Cytomegalovirus (HCMV): HMCV polymerase as drug target Human Cytomegalovirus (HCMV): Inhibitors of HMCV terminase Herpes Simplex Virus (HSV): Targets and inhibitors Adeno Viruses dsDNA Viruses: Antiviral strategies for EBV, human polyoma virus and human herpesvirus 6 ssDNA Viruses: Antiviral strategies for parvovirus B19 Negative-sense ssRNA viruses: Antiviral strategies for Ebola, Marburg, Hendra, Nipah, Lassa, Junin and Machupo viruses Positive-sense ssRNA viruses: Antiviral strategies

Autorenportrait

Helga Rubsamen-Schaeff , PhD, is founding CEO of AiCuris and the chair of AiCuris' Scientific Advisory Board. Before founding AiCuris she served at Bayer as SVP and Head of Infectious Disease Research. Before that time, she was Scientific and Managing Director of the Georg-Speyer-Haus in Frankfurt. A chemist by training, Professor Rubsamen-Schaeff has been professor of biochemistry at the University of Frankfurt since 1988. Her research interests focus on research and development of antiviral drugs, novel resistance-breaking antibiotics, emerging infectious diseases and oncology. Prevymis, a drug against HCMV discovered under her direction has reached the market. Helmut Buschmann, PhD, has over 25 years of international experience in drug discovery research and drug development in the pharmaceutical/biotechnology sectors in different therapeutic areas, from pain research to anti-infectives. Currently, he is Head of Chemistry, Pharmaceutical Development and Patent Affairs at AiCuris and cofounder and co-owner of RD&C Research, Development & Consulting in Vienna.